文献速递中医妇科中药与中成药合理使用

络石内异方通过HIF1A/EZH2/SF-1通路抑制子宫内膜异位症雌二醇合成与炎症

Luoshi Neiyi Prescription inhibits estradiol synthesis and inflammation in endometriosis through the HIF1A/EZH2/SF-1 pathway.
PubMed 文献 · J Ethnopharmacol · 2024-08-02

本研究探讨络石内异方(LSNYP)治疗子宫内膜异位症(EMS)的活性成分及机制。采用UPLC-Q/TOF-MS鉴定成分,并在体外和体内评价其对HIF1A/EZH2/SF-1通路的影响。结果发现LSNYP可抑制雌二醇合成和炎症,提示其可能通过调控该通路发挥治疗EMS的作用。

要点

  • LSNYP含185种成分,可抑制EMS雌二醇合成与炎症。
  • 缺氧环境下HIF1A升高、EZH2降低,导致SF-1表达增加。
  • LSNYP通过调控HIF1A/EZH2/SF-1通路发挥药理效应。

核心结论

  • LSNYP可能通过调控HIF1A/EZH2/SF-1通路抑制雌二醇合成和炎症,从而对EMS发挥药理作用。

研究设计与样本

  • 采用UPLC-Q/TOF-MS鉴定LSNYP化学成分,并分离人原位和异位子宫内膜间质细胞进行体外实验。
  • 体外用氯化钴构建缺氧环境,并通过慢病毒下调和上调HIF1A、EZH2;体内评估LSNYP对HIF1A/EZH2/SF-1通路的影响。

主要发现

  • 在LSNYP中鉴定出185种成分。
  • 异位子宫内膜间质细胞中HIF1A和SF-1的蛋白与基因表达升高,而EZH2表达降低。
  • 50 μmol L-1 CoCl2处理原位子宫内膜间质细胞24 h后,细胞活力和雌二醇(E2)生成增强。
  • 缺氧降低EZH2蛋白表达,而si-HIF1A可增加其表达;EZH2下调时SF-1升高,EZH2过表达则SF-1降低。
  • ChIP显示缺氧减少EZH2与SF-1基因座的结合;体外LSNYP含药血清降低E2和PGE2生成,抑制细胞增殖和侵袭,并降低HIF1A、SF-1、StAR和P450arom表达;体内LSNYP抑制炎症和粘连,并抑制HIF1A/EZH2/SF-1通路。

临床怎么用

  • LSNYP可能作为EMS的候选治疗药物,其作用机制与调控HIF1A/EZH2/SF-1通路相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Endometriosis (EMS) is a common gynecological disease that causes dysmenorrhea, chronic pelvic pain and infertility. Luoshi Neiyi Prescription (LSNYP), a traditional Chinese medicine (TCM) formula, is used to relieve EMS in the clinic. AIMS: This study aimed to examine the active components of LSNYP and the possible mechanism involved in its treatment of EMS. MATERIALS AND METHODS: Ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF-MS) was used to identify the chemical components of LSNYP. Human primary ectopic endometrial stromal cells (ecESCs) and eutopic endometrial stromal cells (euESCs) were isolated, and the expression levels of hypoxia inducible factor 1A (HIF1A), enhancer of zeste homolog 2 (EZH2) and steroidogenic factor 1 (SF-1) were detected by immunofluorescence and qPCR. Cobalt chloride (CoCl2) was utilized to construct an in vitro hypoxic environment, and lentiviruses were engineered to downregulate HIF1A and EZH2 and upregulate EZH2. Subsequently, the expression levels of HIF1A, EZH2, and SF-1 were measured using qPCR or western blotting. The binding of EZH2 to the SF-1 locus in ESCs was examined via ChIP. Furthermore, the effects of LSNYP on the HIF1A/EZH2/SF-1 pathway were evaluated both in vitro and in vivo. RESULTS: A total of 185 components were identified in LSNYP. The protein and gene expression levels of HIF1A and SF-1 were increased, whereas those of EZH2 were decreased in ecESCs. After treating euESCs with 50 μmol L-1 CoCl2 for 24 h, cell viability and estradiol (E2) production were enhanced. Hypoxia decreased EZH2 protein expression, while si-HIF1A increased it. SF-1 was increased when EZH2 was downregulated in normal and hypoxic environments, whereas the overexpression of EZH2 led to a decrease in SF-1 expression. ChIP revealed that hypoxia reduced EZH2 binding to the SF-1 locus in euESCs. In vitro, LSNYP-containing serum decreased E2 and prostaglandin E2 (PGE2) production, inhibited cell proliferation and invasion, and reduced the expression of HIF1A, SF-1, steroidogenic acute regulatory protein (StAR), and aromatase cytochrome P450 (P450arom). In vivo, LSNYP suppressed inflammation and adhesion and inhibited the HIF1A/EZH2/SF-1 pathway in endometriotic tissues. CONCLUSIONS: LSNYP may exert pharmacological effects on EMS by inhibiting E2 synthesis and inflammation through regulation of the HIF1A/EZH2/SF-1 pathway. These results suggest that LSNYP may be a promising candidate for the treatment of EMS.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wu L, Lan D, Sun B, et al. Luoshi Neiyi Prescription inhibits estradiol synthesis and inflammation in endometriosis through the HIF1A/EZH2/SF-1 pathway. J Ethnopharmacol. 2024. PMID: 39098622. doi:10.1016/j.jep.2024.118659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。